Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Head Neck ; 2024 May 02.
Article in English | MEDLINE | ID: mdl-38695445

ABSTRACT

BACKGROUND: The purpose of this study was to provide further insights into whether age and/or sex are associated with prognosis in oral tongue squamous cell carcinoma. METHODS: This was a retrospective cohort study utilizing hospital registry data from 2006 to 2016 obtained from the National Cancer Database. Identified patients were divided into various cohorts based on age, sex, and staging. A descriptive analysis was performed using chi-square tests and overall survival rates were estimated using Kaplan-Meier method. RESULTS: A total of 17 642 patients were included in the study. The 5-year overall survival rates were 82.0% (95% CI: 79.8%-84.0%) in younger patients versus 67.5% (95% CI: 66.7%-68.3%, p-value <0.0001) older patients. The median overall survival for females was 143.4 months (95% CI: 133.2-NA) versus 129.8 (95% CI: 125.4-138.7, p-value <0.0001) in males. CONCLUSIONS: Our analysis suggests that younger age and female sex are both predictors of improved survival in oral tongue squamous cell carcinoma.

2.
Crit Rev Oncol Hematol ; 116: 125-133, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28693794

ABSTRACT

Adipose tissue synthesizes many proteins and hormones collectively called adipokines, which are linked to a number of diseases, including cancer. Low levels of adiponectin are reported to be a risk factor for obesity-related cancers including colorectal and prostate cancers. Accordingly, obesity/lifestyle-related diseases, including certain cancers, may be treated by developing drugs that act specifically on adiponectin levels in circulation. Adiponectin may also serve as a clinical biomarker in obesity-related diseases. Adiponectin-based therapies are known to inhibit cancer advancement and thus may provide a therapeutic approach to delay cancer progression. Better understanding of the function of adiponectin is of great significance in the fight against cancer. This timely review is concentrated on the role of adiponectin and the impact of obesity on the development of cancers, especially colorectal and prostate cancers.


Subject(s)
Adiponectin/metabolism , Colonic Neoplasms/etiology , Obesity/complications , Prostatic Neoplasms/etiology , Animals , Colonic Neoplasms/metabolism , Humans , Male , Obesity/metabolism , Prostatic Neoplasms/metabolism , Risk Factors
3.
Cytokine Growth Factor Rev ; 31: 37-48, 2016 10.
Article in English | MEDLINE | ID: mdl-27079372

ABSTRACT

Adipose tissue is a highly vascularized endocrine organ, and its secretion profiles may vary with obesity. Adiponectin is secreted by adipocytes that make up adipose tissue. Worldwide, obesity has been designated a serious health problem among women and is associated with a variety of metabolic disorders and an increased risk of developing cancer of the cervix, ovaries, uterus (uterine/endometrial), and breast. In this review, the potential link between obesity and female-specific malignancies is comprehensively presented by discussing significant features of the intriguing and complex molecule, adiponectin, with a focus on recent findings highlighting its molecular mechanism of action in female-specific carcinogenesis.


Subject(s)
Adiponectin/metabolism , Carcinogenesis/metabolism , Obesity/complications , Obesity/metabolism , Female , Humans , Neoplasms/etiology , Neoplasms/metabolism , Receptors, Adiponectin/metabolism
4.
Expert Opin Drug Discov ; 9(2): 201-14, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24303998

ABSTRACT

INTRODUCTION: The measles virus is a major human pathogen responsible for approximately 150,000 deaths annually. The disease is vaccine preventable and eradication of the virus is considered feasible, in principle. However, a herd immunity exceeding 95% is required to prevent sporadic viral outbreaks in a population. Declining disease prevalence, combined with public anxiety over the vaccination's safety, has led to increased vaccine refusal, especially in Europe. This has led to the resurgence of measles in some areas. AREAS COVERED: This article discusses whether synergizing effective measles therapeutics with the measles vaccination could contribute to finally eradicating measles. The authors identify key elements in a desirable drug profile and review current disease management strategies and the state of experimental inhibitor candidates. The authors also evaluate the risk associated with viral escape from inhibition, and consider the potential of measles therapeutics in the management of persistent central nervous system (CNS) viral infection. Finally, the authors contemplate the possible impact of therapeutics in controlling the threat imposed by closely related zoonotic pathogens of the same genus as measles. EXPERT OPINION: Efficacious therapeutics used for post-exposure prophylaxis of high-risk social contacts of confirmed index cases may aid measles eradication by closing herd immunity gaps; this is due to vaccine refusal or failure in populations with overall good vaccination coverage. The envisioned primarily prophylactic application of measles therapeutics to a predominantly pediatric and/or adolescent population, dictates the drug profile. It also has to be safe and efficacious, orally available, shelf-stable at ambient temperature and amenable to cost-effective manufacturing.


Subject(s)
Disease Eradication/methods , Measles/prevention & control , Animals , Antiviral Agents/therapeutic use , Drug Resistance, Viral , Humans , Measles/complications , Measles/physiopathology , Measles Vaccine , Vaccination
5.
Int J Radiat Oncol Biol Phys ; 69(2 Suppl): S132-5, 2007.
Article in English | MEDLINE | ID: mdl-17848282

ABSTRACT

Head and neck squamous cell carcinoma affects >45,000 Americans annually. Patients who are successfully treated for their primary tumor are at high risk of developing a second primary tumor, making effective preventive strategies highly desirable for this disease. Although a landmark study in 1990 suggested some benefit of high-dose retinoids in head and neck cancer prevention, subsequent trials using more tolerable doses have shown limited clinical success. Newer preventive strategies have included bioadjuvant therapy combining retinoids with interferon and alpha-tocopherol, combinations of molecularly targeted agents, and oncolytic viruses. Furthermore, considerable evidence has supported a cancer protective role for several nutrients, including green tea and curcumin analogs. Natural compounds such as these with favorable long-term safety profiles might be particularly suited to the cancer prevention setting, in which patients will usually tolerate only moderate risk and toxicity.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Carcinoma, Squamous Cell/prevention & control , Head and Neck Neoplasms/prevention & control , Neoadjuvant Therapy/methods , Retinoids/therapeutic use , Adenoviridae , Cyclooxygenase 2 Inhibitors/therapeutic use , Diterpenes , ErbB Receptors/antagonists & inhibitors , Etretinate/therapeutic use , Humans , Interferon-alpha/therapeutic use , Isotretinoin/therapeutic use , Randomized Controlled Trials as Topic , Retinyl Esters , Viral Vaccines , Vitamin A/analogs & derivatives , Vitamin A/therapeutic use
7.
J Virol ; 76(10): 5051-61, 2002 May.
Article in English | MEDLINE | ID: mdl-11967321

ABSTRACT

To understand the molecular determinants of measles virus (MV) cytopathicity, we have characterized mutant viruses exhibiting a more-extensive cell-to-cell fusion while maintaining efficient replication to high titers. A virus which is modified by the addition of an 8-amino-acid Flag epitope tag at the cytoplasmic tail of its H (for MV hemagglutinin) envelope glycoprotein replicates efficiently, has an increased cytopathicity, possesses a greater infectivity per particle, and has an altered protein composition compared with that of unmodified MV. The mutant phenotype is not specifically linked to the epitope sequence, since an alternatively added HA (for influenza virus-derived hemagglutinin) epitope tag caused similar effects. We demonstrate that both epitope tags weaken the interaction between the H and fusion (F) glycoproteins in virus-infected cells. This reduction in strength of H/F interaction is independent of the presence of the viral matrix (M) protein. Viruses with this less stable complex are more sensitive to neutralization by a soluble octameric form of the CD46 receptor, consistent with their increased fusogenicity. Similar analyses of glycoproteins derived from MV strains with reduced cytopathicities confirm that the strength of H and F glycoprotein interaction is a modulator of viral fusogenicity.


Subject(s)
Glycoproteins/metabolism , Measles virus/pathogenicity , Viral Envelope Proteins/metabolism , Animals , Chlorocebus aethiops , Cytopathogenic Effect, Viral , Epitopes/genetics , Giant Cells , HeLa Cells , Hemagglutinins, Viral/genetics , Hemagglutinins, Viral/metabolism , Humans , Measles virus/genetics , Measles virus/metabolism , Oligopeptides , Peptides/genetics , Recombination, Genetic , Vero Cells
SELECTION OF CITATIONS
SEARCH DETAIL
...